| Aktie | Ticker | Breite | GCS | 2026/Q2 | 2026/Q1 | 2025/Q4 | 2025/Q3 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 147.284.336 $ | +35.458.803 $ | +26,8 % | 3 | 111.825.533 $ | +2.801.575 $ | +5,3 % | 3 | 109.023.958 $ | +26.120.219 $ | +31,6 % | 3 | 82.903.739 $ | +9.604.192 $ | +75,8 % | 3 | ||||
| Bicara Therapeutics Inc. | BCAX | → 0 | Neutral | 93.924.820 $ | +30.863.396 $ | +48,9 % | 1 | 63.061.424 $ | +9.701.758 $ | +18,2 % | 1 | 53.359.666 $ | +3.297.329 $ | +6,6 % | 1 | 50.062.337 $ | +20.608.308 $ | +70,0 % | 1 |
| Ceribell, Inc. | CBLL | → 0 | Neutral | 42.900.106 $ | +2.470.340 $ | +6,1 % | 1 | 40.429.766 $ | -7.940.380 $ | -16,4 % | 1 | 48.370.146 $ | +23.027.101 $ | +90,9 % | 1 | 25.343.045 $ | -15.968.986 $ | -38,7 % | 1 |
| Contineum Therapeutics, Inc. | CTNM | → 0 | Schwach | 10.459.410 $ | +2.125.067 $ | +25,5 % | 1 | 8.334.343 $ | +1.040.197 $ | +14,3 % | 1 | 7.294.146 $ | -204.211 $ | -2,7 % | 1 | 7.498.357 $ | +4.964.870 $ | +196,0 % | 1 |
| 147.284.336 $ | +35.458.803 $ | +26,8 % | 3 | 111.825.533 $ | +2.801.575 $ | +5,3 % | 3 | 109.023.958 $ | +26.120.219 $ | +31,6 % | 3 | 82.903.739 $ | +9.604.192 $ | +75,8 % | 3 | ||||